AVTX - CIK 0001534120
The table below shows Avalo Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.86M | $134.55M | $7.42M | $13.17M | $54.59M | $18.92M |
| Short-term investments | $82.48M | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | $0.00 | $20.00K | $38.00K | $3.14K |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $105.29M |
| $138.89M |
| $8.39M |
| $16.42M |
| $61.84M |
| $26.01M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | $10.50M | $10.50M | $10.50M | $14.41M | $14.41M | $14.41M |
| Total assets | $116.46M | $150.73M | $20.99M | $33.37M | $80.21M | $43.76M |
| Accounts payable | $137.00K | $283.00K | $446.00K | $2.88M | $3.37M | $2.57M |
| Total current liabilities | $12.94M | $6.96M | $4.62M | $22.11M | $19.89M | $15.22M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $33.41M | $17.70M | $13.69M | $44.28M | $57.13M | $19.19M |
| Retained earnings | -$448.52M | -$370.26M | -$335.13M | -$303.82M | -$262.17M | -$177.79M |
| Total equity | $83.05M | $133.03M | $7.30M | -$10.91M | $23.08M | $24.56M |